- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00371189
Adenovirus Vaccine for Malaria
September 18, 2014 updated by: National Institute of Allergy and Infectious Diseases (NIAID)
A Phase I Randomized, Controlled, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Healthy Adults 18 to 45 Years of Age
Malaria is caused by a parasite carried by a mosquito.
Currently, there is no vaccine licensed to prevent malaria.
The purpose of this study is to find the most effective and safest dose of an experimental vaccine for the treatment of malaria.
Participants will include 72 healthy adults, ages18 to 45, enrolled at Vanderbilt University Medical Center and Stanford University.
Volunteers will receive 3 doses of either the malaria vaccine or placebo (contains no vaccine) by injection into a muscle at 0, 1 and 6 months.
Investigators will evaluate how the body responds to increasing dosage strengths of the vaccine.
Study procedures include physical exam, multiple blood draws, and completion of a memory aid (diary).
Each participant will be actively involved in the study for about 12 months.
Then, an annual phone call will be made to check for any serious illness events for a period of 5 years.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Malaria currently represents one of the most prevalent infections in tropical and subtropical areas throughout the world.
Each year, malaria affects around 300 million people and kills 1 to 3 million people in developing countries.
The widespread occurrence and the growing incidence of malaria are a consequence of the increasing numbers of drug-resistant parasites and insecticide-resistant parasite vectors.
Other factors include environmental and climatic changes, civil disturbances and increased mobility of populations.
It is hypothesized that the Ad35.CS.01 vaccine will prevent the Plasmodium (P.) falciparum parasite, which causes malaria, from entering and developing within the liver of those who become infected.
Ad35.CS.01 would therefore be expected to reduce malaria-attributable morbidity and mortality.
The purpose of this phase I, randomized, controlled, dosage-escalation trial is to evaluate the immunogenicity, safety, and reactogenicity of an Adenovirus Type 35 based circumsporozoite malaria vaccine in 72 healthy adults, 18 to 45 years of age, in the United States.
Subjects will be randomized in a 5:1 ratio to receive 3 doses of the Adenovirus Type 35 circumsporozoite malaria vaccine (Ad35.CS.01) or normal saline placebo control by the intramuscular route at 0, 1 and 6 months.
The safety, reactogenicity, and immunogenicity of ascending dosages of the vaccine will be assessed.
Fifteen subjects will receive vaccine at each of the following dosage levels: 10^8 viral particles (vp)/milliliters (ml), 10^9 vp/ml, 10^10 vp/ml and 10^11 vp/ml with 3 subjects receiving control at each of these dosage levels.
Dosage escalation will proceed only after review of the safety data by the Safety Monitoring Committee of the prior dosage level.
The primary objective is to assess the safety and reactogenicity of ascending dosages of Adenovirus Type 35 based circumsporozoite malaria vaccine among healthy subjects given in 3 intramuscular doses at 0, 1 and 6 months.
The secondary objective is to evaluate the immunogenicity of the Adenovirus Type 35 based circumsporozoite malaria vaccine through performance of Humoral Immune Assays [ELISA (enzyme-linked immunosorbent assay)] for antibodies to circumsporozoite antigen and Adenovirus Neutralization Assay for neutralizing antibodies to Adenovirus type 35) and Cellular Immune Assays [enzyme-linked immunosorbent spot (ELISPOT) and Flow Cytometry] for circumsporozoite (CS)-specific cluster of differentiation (CD)4+ and CD8+ T cell responses.
Study Type
Interventional
Enrollment (Actual)
75
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305-2200
- Stanford University School of Medicine
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232-2573
- Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provision of informed consent before any protocol procedures are performed.
- Males and non-pregnant females between the ages of 18 and 45 years, inclusive.
- Females and males must agree to practice adequate contraception until at least 28 days following their last immunization dose (including abstinence; hormonal contraception; condoms with spermicidal agents; post-menopausal; or surgical sterilization/vasectomy).
- Participants must agree to avoid high risk sexual behavior for exposure to human immunodeficiency virus (HIV).
- In good health as determined by screening medical history, physical examination (PE), and laboratory assessments.
- Willingness to comply with protocol requirements.
- Willingness to be contacted annually for five years for assessment of serious adverse events.
- Must have access to a cell phone.
Exclusion Criteria:
- Current or recent (within the last four weeks) treatment with parenteral, inhaled, or oral corticosteroids (intranasal steroids are acceptable), or other immunosuppressive agents, or chemotherapy.
- History of splenectomy.
- Abnormal screening laboratory values. Any abnormal screening value for any screening test will exclude the subject from the study. Abnormal screening labs will not be repeated with the exception of high glucose levels will be repeated at a fasting state.
- Detectible neutralizing antibody titer against adenovirus serotype 35.
- History of intravenous (IV) drug abuse.
- History of, or current medical, occupational, social or family problems as a result of alcohol or illicit drug use.
- History of moderate to severe mental illness, as defined by symptoms interfering with social or occupational function or suicidal thoughts/attempts.
- History of receiving blood or blood products (such as blood transfusion, platelet transfusion, immunoglobulins, hyperimmune serum) in the previous 6 months.
- Vaccination with a live vaccine within the past 30 days or with a nonreplicating, inactivated, or subunit vaccine within the last 14 days.
- Known hypersensitivity to components of the vaccine.
- History of acute or chronic medical conditions including, but not limited to, disorders of the liver, kidney, lung, heart, or nervous system, or other metabolic or autoimmune/inflammatory conditions.
- History of coagulation defect or bleeding from (bruising at) multiple sites that cannot be linked to trauma or surgery.
- History of anaphylaxis or severe hypersensitivity reaction.
- Severe asthma, as defined by an emergency room visit or hospitalization within the last 12 months.
- Pregnant or breastfeeding women.
- Acute illness, including temperature greater than 100 degrees Fahrenheit within one week prior to vaccination.
- Positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg).
- Concurrent participation in other investigational protocols or receipt of an investigational product within the previous 30 days or planned receipt of an investigational product within 28 days following the last immunization dose.
- Identification of any condition that, in the opinion of the investigator, would affect the ability of the subject to understand or comply with the study protocol or would jeopardize the safety or rights of a subject participating in the study.
- History of malignancy, including hematologic and skin cancers (except for a localized basal cell carcinoma), or known immunodeficiency syndrome.
- History of malaria infection or previous receipt of a malaria vaccine.
- History of travel to malaria-endemic area or receipt of antimalarial prophylaxis in the past 12 months.
- Planned travel to a malaria-endemic area prior to Visit 16 (Day 208).
- Pre-medication with analgesic or antipyretic agents in the 6 hours prior to vaccination, or planned medication with analgesic or antipyretic in the 24 hours following vaccination. This criterion should not preclude subjects receiving such medication if the need arises.
- Receipt of a recombinant adenovirus vector vaccine in a prior study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group C: Ad35.CS.01-10^10 vp/ml
15 subjects will receive dosage 10^10 vp/mL; 3 subjects will receive placebo.
|
Normal saline.
Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10^8 viral particles (vp)/mL, 10^9 vp/mL, 10^10 vp/mL and 10^11 vp/mL.
|
Experimental: Group D: Ad35.CS.01-10^11 vp/ml
15 subjects will receive dosage 10^11 vp/mL; 3 subjects will receive placebo.
|
Normal saline.
Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10^8 viral particles (vp)/mL, 10^9 vp/mL, 10^10 vp/mL and 10^11 vp/mL.
|
Experimental: Group A: Ad35.CS.01-10^8 vp/ml
15 subjects will receive dosage 10^8 vp/mL; 3 subjects will receive placebo.
|
Normal saline.
Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10^8 viral particles (vp)/mL, 10^9 vp/mL, 10^10 vp/mL and 10^11 vp/mL.
|
Experimental: Group B: Ad35.CS.01-10^9 vp/ml
15 subjects will receive dosage 10^9 vp/mL; 3 subjects will receive placebo.
|
Normal saline.
Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10^8 viral particles (vp)/mL, 10^9 vp/mL, 10^10 vp/mL and 10^11 vp/mL.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency and severity of local, systemic, and safety laboratory adverse events.
Time Frame: Enrollment through to Day 208
|
Enrollment through to Day 208
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
T cell responses against the malaria circumsporozoite antigen by enzyme-linked immunosorbent spot (ELISPOT) and flow cytometry.
Time Frame: Days 28, 56, 120, 180, 208.
|
Days 28, 56, 120, 180, 208.
|
Antibody titers against the malaria circumsporozoite antigen via enzyme-linked immunosorbent assay (ELISA).
Time Frame: Days 28, 56, 120, 180, 208.
|
Days 28, 56, 120, 180, 208.
|
Neutralizing antibody titers against Adenovirus type 35 by Adenovirus Neutralization Assay.
Time Frame: Days 28, 56, 120, 180, 208.
|
Days 28, 56, 120, 180, 208.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
June 1, 2014
Study Completion (Actual)
June 1, 2014
Study Registration Dates
First Submitted
August 31, 2006
First Submitted That Met QC Criteria
August 31, 2006
First Posted (Estimate)
September 1, 2006
Study Record Updates
Last Update Posted (Estimate)
September 22, 2014
Last Update Submitted That Met QC Criteria
September 18, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05-0050
- N01AI80007C
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plasmodium Falciparum Infection
-
SanofiMedicines for Malaria VentureCompletedPlasmodium Falciparum InfectionBenin, Burkina Faso, Gabon, Kenya, Uganda
-
SanofiMedicines for Malaria VentureTerminatedPlasmodium Falciparum InfectionBenin, Burkina Faso, Gabon, Kenya, Mozambique, Uganda, Vietnam
-
Papua New Guinea Institute of Medical ResearchSwiss Tropical & Public Health Institute; Walter and Eliza Hall Institute of... and other collaboratorsCompletedPlasmodium Falciparum Infection | Plasmodium Vivax Infection | Plasmodium Vivax Clinical Episode | Plasmodium Falciparum Clinical EpisodePapua New Guinea
-
Radboud University Medical CenterErasmus Medical Center; The PATH Malaria Vaccine Initiative (MVI); Havenzieke...CompletedPlasmodium Falciparum | Malaria,Falciparum | Plasmodium Berghei | Controlled Human Malaria Infection (CHMI)Netherlands
-
Menzies School of Health ResearchWorld Health Organization; Eijkman Institute for Molecular BiologyCompletedPlasmodium Falciparum Infection | Plasmodium Vivax InfectionIndonesia
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedPlasmodium Falciparum InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedPlasmodium Falciparum InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States